D-Arg8-Cetrorelix substitutes a D-arginine at position 8, modifying backbone stereochemistry and proteolytic susceptibility. The guanidinium side chain remains cationic, but local geometry is significantly shifted. Researchers compare receptor affinity and structural stability relative to the L-form. Applications include analog-based SAR, peptide stabilization strategies, and conformational-enforcement studies.
CAT No: Z10-101-209
Synonyms/Alias:(S)-1-(((R)-2-((S)-2-((S)-2-((R)-2-((R)-2-((R)-2-acetamido-3-(naphthalen-2-yl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(pyridin-3-yl)propanamido)-3-hydroxypropanamido)-3-(4-hydroxyphenyl)propanamido)-5-ureidopentanoyl)-L-leucyl-D-arginyl)-N-((R)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide; (S)-1-(((R)-2-((S)-2-((S)-2-((R)-2-((R)-2-((R)-2-acetamido-3-(naphthalen-2-yl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(pyridin-3-yl)propanamido)-3-hydroxypropanamido)-3-(4-hydroxyphenyl)propanamido)-5-ureidopentanoyl)-L-leucyl-D-arginyl)-N-((R)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide
D-Arg8-Cetrorelix is a synthetic peptide analog derived from the gonadotropin-releasing hormone (GnRH) antagonist family, characterized by the substitution of eight D-arginine residues to enhance its biochemical stability and receptor affinity. As a potent peptide inhibitor of GnRH-mediated signaling, it is widely recognized for its utility in the investigation of reproductive endocrinology, peptide-receptor interactions, and the modulation of hormone-driven cellular processes. The unique structural modifications confer increased resistance to enzymatic degradation, making it a valuable tool for researchers exploring peptide stability, receptor selectivity, and downstream signaling mechanisms in vitro and in vivo. Its distinct profile as a modified decapeptide enables precise interrogation of neuroendocrine pathways and supports advanced experimental designs in peptide-based research.
Peptide-receptor interaction studies: D-Arg8-Cetrorelix serves as a robust molecular probe for dissecting the binding dynamics between GnRH antagonists and their cognate receptors. The enhanced affinity and stability resulting from D-arginine substitution facilitate prolonged receptor engagement, allowing detailed kinetic and structural analyses. Researchers employ this analog in competitive binding assays, receptor mapping studies, and structure-activity relationship experiments to elucidate the determinants of ligand specificity and antagonist potency in the context of GnRH receptor modulation.
Endocrine pathway modulation: As a selective GnRH antagonist, D-Arg8-Cetrorelix is instrumental in experiments aimed at suppressing gonadotropin release within pituitary cell models or tissue explants. By competitively inhibiting endogenous GnRH, it enables precise temporal and quantitative control over luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in vitro. This property supports investigations into hormonal feedback loops, pituitary gland physiology, and the regulatory mechanisms governing reproductive hormone synthesis and secretion.
Peptide stability and pharmacokinetic research: The incorporation of multiple D-arginine residues in D-Arg8-Cetrorelix offers a unique opportunity to study the impact of stereochemical modification on peptide half-life, proteolytic resistance, and bioavailability. Researchers utilize this analog to compare metabolic stability profiles with L-amino acid-containing peptides, informing the design of next-generation peptide therapeutics and delivery systems. Such studies are crucial for advancing the understanding of how peptide modification strategies can optimize biological activity and duration of action in research settings.
Cell signaling and functional assays: D-Arg8-Cetrorelix is frequently applied in cell-based assays to investigate downstream signaling cascades initiated by GnRH receptor antagonism. Its ability to block GnRH-mediated activation of intracellular pathways, such as the phospholipase C and protein kinase C routes, provides a controlled model for dissecting signal transduction events. These experiments yield insights into the broader physiological roles of GnRH signaling in non-reproductive tissues and contribute to the characterization of receptor-mediated cellular responses.
Peptide synthesis and method development: The structural complexity and sequence modifications present in D-Arg8-Cetrorelix make it a preferred standard in the development and validation of solid-phase peptide synthesis protocols. Its use as a model system assists in optimizing coupling strategies, purification methods, and analytical characterization techniques for challenging peptide sequences. Researchers benefit from its application in troubleshooting synthetic bottlenecks and refining methodologies for the efficient production of highly modified peptide analogs, thereby supporting innovation in peptide chemistry and biotechnological applications.
4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More